1. Scrip
  2. >>Business
  3. >>Financing

ReNAgade Emerges With $300m To Pursue Extra-Hepatic Delivery Of RNA Medicines

New CEO Amit Munshi Last Helmed Arena

 
• By Mandy Jackson

ReNAgade Therapeutics came out of stealth mode with $300m to fund its proprietary technology for delivery of RNA medicines – including coding, editing and gene insertion modalities – beyond the liver.

Notepad with "venture capital" written on it
ReNAgade's series A is one of the largest VC rounds so far in 2023 • Source: Shutterstock

ReNAgade Therapeutics has been hard at work for more than 18 months building proprietary technologies, including lipid nanoparticles (LNPs), that are designed to deliver RNA medicines of all kinds beyond the liver to any tissue or cell type necessary to treat a disease. It has a high-profile partnership under its belt and has shown that its technology works in non-human primates, but it is just now emerging from stealth mode, with $300m in series A venture capital and a new CEO.

Cambridge, MA-based ReNAgade announced its first big round of financing on 23 May and named Amit Munshi – previously CEO of Arena Pharmaceuticals, Inc. when it was acquired by Pfizer Inc. in 2022 for $6.7bn – as its chief executive. (Also see "Pfizer Buys Arena For $6

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

HAYA Raises $65m To Take First Long Non-Coding RNA Program Into The Clinic

 
• By Mandy Jackson

HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Switzerland Biopharma To Stay Strong Despite More Cash Going To US And China

 
• By Kevin Grogan

The sector is continuing to show resilience despite financial and market challenges.

More from Business

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

HAYA Raises $65m To Take First Long Non-Coding RNA Program Into The Clinic

 
• By Mandy Jackson

HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’